Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ribon Therapeutics
Cambridge, Massachusetts, United Statesribontx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ribon Therapeutics was a clinical-stage biotech company developing first-in-class small molecule inhibitors targeting novel stress response pathways, especially monoPARPs such as PARP7 and PARP14. Its lead oncology program, RBN‑2397, advanced through Phase 1 and into Phase 1b/2 combination studies with pembrolizumab for squamous cell carcinoma of the lung. The second program, RBN‑3143—a PARP14 inhibitor—entered Phase 1 trials for atopic dermatitis. Despite strong investor backing and partnerships with major pharma companies, the company ceased operations in August 2024 after nearly a decade in business.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Otsuka PharmaceuticalBoehringer IngelheimAbbVie VenturesBristol Myers Squibb/BMS VenturesJ&J Innovation/JJDC Inc.Novartis Venture FundPfizer Ventures
Beyond the preview
Go deeper on Ribon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribon Therapeutics.